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Abstract
Background: TGFβ1-induced expression of transforming growth factor β-induced protein (TGFBIp) and extracellular
matrix (ECM) genes plays a major role in the development of granular corneal dystrophy type 2 (GCD2: also called
Avellino corneal dystrophy). Although some key transcription factors are known, the epigenetic mechanisms
modulating TGFBIp and ECM expression remain unclear. We examined the role of chromatin markers such as
histone H3 lysine methylation (H3Kme) in TGFβ1-induced TGFBIp and ECM gene expression in normal and GCD2-
derived human corneal fibroblasts.
Methods: Wild-type (n = 3), GCD2-heterozygous (n = 1), and GCD2-homozygous (n = 3) primary human corneal
fibroblasts were harvested from human donors and patients prepared. Microarray and gene-expression profiling,
Chromatin immunoprecipitation microarray analysis, and Methylated DNA isolation assay-assisted CpG microarrays
was performed in Wild-type and GCD2-homozygous human cells.
Results: Transcription and extracellular-secretion levels of TGFBIp were high in normal cells compared with those in
GCD2-derived cells and were related to H3K4me3 levels but not to DNA methylation over the TGFBI locus. TGFβ1
increased the expression of TGFBIp and the ECM-associated genes connective tissue growth factor, collagen-α2[Ι],
and plasminogen activator inhibitor-1 in normal corneal fibroblasts. Increased levels of gene-activating markers
(H3K4me1/3) and decreased levels of repressive markers (H3K27me3) at the promoters of those gene accompanied
the changes in expression. TGFβ1 also increased recruitment of the H3K4 methyltransferase MLL1 and of SET7/9
and also the binding of Smad3 to the promoters. Knockdown of both MLL1 and SET7/9 significantly blocked the
TGFβ1-induced gene expression and inhibited TGFβ1-induced changes in promoter H3K4me1/3 levels. Those
effects were very weak, however, in GCD2-derived corneal fibroblasts.
Conclusions: Taken together, the results show the functional role of H3K4me in TGFβ1-mediated TGFBIp and ECM
gene expression in corneal fibroblasts. Pharmacologic and other therapies that regulate these modifications could
have potential cornea-protective effects for granular corneal dystrophy.
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Background
Granular corneal dystrophy type 2 (GCD2, also called
Avellino corneal dystrophy) is an autosomal dominant
disorder caused by an arginine-to-histidine substitution
at codon 124 (R124H) of the transforming growth factor
β-induced gene (TGFBI) on chromosome 5q31.8. TGFBI
encodes a protein of 683 amino acids (TGFBIp) [1, 2].
TGFBIp is an extracellular matrix (ECM) protein that is
structurally homologous to the axon-guidance protein
fasciclin I [3–5]. TGFBIp contains four tandem repeats
of fasciclin I domains and an EMI protein-protein
interaction domain and plays a key role in a variety
of cellular responses including adhesion, migration,
proliferation, angiogenesis, and wound healing [6–8].
The age-dependent, progressive accumulation of hyaline
and amyloid-containing TGFBIp in the corneal stroma is
a hallmark of GCD2, which is characterized by the pro-
duction of TGFBIp in the corneal epithelia and stroma,
interfering with corneal transparency [9]. Moreover,
homozygous R124H mutations in TGFBI cause the severe
phenotype of GCD2 characterized by early onset and con-
fluent superficial opacity [10, 11]. The molecular mecha-
nisms and cellular role of TGFBIp in corneal dystrophy
pathogenesis are poorly understood.
TGFβ1 induces the progressive accumulation of
TGFBIp and ECM proteins such as collagens, fibro-
nectin, and keratin in the corneal epithelia and stroma
[12–14]. TGFβ1 increases ECM accumulation through the
induction of its downstream effector, connective tissue
growth factor (CTGF) [15, 16], and by decreasing matrix
degradation through the inhibition of proteases or the ac-
tivation of protease inhibitors such as plasminogen activa-
tor inhibitor-1 (PAI-1) in glomerular mesangial cells [17].
TGFβ1 can regulate TGFBIp expression through Smad
transcription factors and E-box-dependent mechanisms
[18–22]. However, the subtle nuclear-chromatin mecha-
nisms involved in the TGF-β1-induced expression of key
ECM genes in corneal fibroblasts are not clear.
Gene regulation by extracellular stimuli involves not
only transcription factors binding to their cognate DNA
binding sites but also epigenetic changes in chromatin
without alterations in DNA sequence. Post-translational
modifications, including acetylation, methylation, and
ubiquitination at key lysines, on the amino-terminal tails
of nucleosomal histones such as H3 and H4 play a key
role in modulating chromatin structure and gene tran-
scription [23, 24]. They form a “histone code” that can
dictate the transcriptional outcomes of gene activation
or repression [25]. In general, the acetylation of H3 ly-
sines (H3KAc) is associated with active gene transcrip-
tion, whereas the methylation of H3 lysines (H3Kme)
can be associated with either active or inactive gene pro-
moters, depending on the position of the modified ly-
sine. H3KAc is mediated by histone acetyl transferases,
whereas H3Kme is mediated by histone methyltransfer-
ases (HMTs). HMTs can mono-methylate, di-methylate,
or tri-methylate (H3Kme1, H3Kme2, or H3Kme3, re-
spectively) specific lysine residues, thereby adding an-
other epigenetic regulatory layer [24].
The methylation of the fourth lysine in H3 (H3K4me)
is usually associated with gene activation and transcrip-
tional elongation and is mediated by HMTs such as
SET1, MLL1-4, and SET7/9 [24, 26–28]. H3K9me, on
the other hand, is generally associated with gene repres-
sion and is mediated by HMTs such as SUV39H1, G9a,
and SETDB1/ESET [26]. Other H3 lysines, including
H3K27, H3K36, and H3K79, can also be methylated to
various degrees [26]. In addition, the discovery of his-
tone lysine demethylases has added another dimension
to gene regulation [29]. Together, these factors create a
fine balance of gene regulation, a disruption of which
could result in abnormal gene expression and disease
phenotypes.
It is not known whether lysine methylation in the H3
promoter plays a role in the TGFβ1-induced transcrip-
tion of TGFBIp and ECM-associated genes in corneal fi-
broblasts. Here, we show that the transcription and
ECM secretion levels of TGFBIp are high in normal cells
compared with those in GCD2 cells and are related to
H3K4me3 levels. We also show that TGFβ1 leads to
the enrichment of H3K4me1/3 and the depletion of
H3K27me3 markers on the promoters of TGFBIp and
ECM-associated genes in corneal fibroblasts. Furthermore,
H3K4, HMT, MLL1, and SET7/9 all seemed to play a role
in the TGFβ1-induced expression of TGFBIp and ECM
genes. These data show novel epigenetic mechanisms of
TGFβ1 actions in corneal fibroblasts related to TGFBIp
and ECM deposition and GCD2 pathogenesis.
Methods
Materials
Recombinant TGFβ1 was obtained from R&D Systems
(Minneapolis, MN); normal rabbit IgG, normal mouse
IgG, and ChIP-Grade Protein A/G Magnetic Beads were
obtained from Thermo Scientific, (Rockford, IL, USA).
The following antibodies were used in western-blot ana-
lyses and ChIP assays: anti-smad3 (ab28379), anti-SET7/
9 (ab13731), anti-histone H3 (ab100938), anti-histone
H3 trimethyl K9 (ab8898), and anti-H3 trimethyl K27
(ab1782) from Abcam (Cambridge, MA); anti-MLL1
(05–765), anti-H3 monomethyl K4 (07–436), and anti-
H3 trimethyl K4 (07–473) from Millipore (Millipore
Corp., Bedford, MA); anti-TGFBIp (AF2935) from R&D
Systems; and anti-β-actin (A-5441) from Sigma-Aldrich
(St. Louis, MO). MLL1 shRNA lentivirus (sc-38039-v),
SET7/9 shRNA lentivirus (sc-44094-v), and control
shRNA lentivirus (sc-108080) was purchased from Santa
Cruz Biotechnology Inc. (Heidelberg, Germany).
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Isolation and culture of primary corneal fibroblasts
Wild-type (n = 2) and GCD2-homozygous (n = 2)
(Arg124His mutation) primary human corneal fibroblasts
were harvested from human donors (age matched) and
patients prepared using a previously published method
[30]. Donor confidentiality was maintained according to
the Declaration of Helsinki, and the Severance Hospital
IRB Committee (CR04124), Yonsei University approved
the protocol. The wild-type and GCD2 cells were diag-
nosed by DNA sequencing of TGFBI mutations. After the
removal of the corneal buttons from the donors for pene-
trating keratoplasty, the remaining corneal rims were har-
vested for culture of the corneal fibroblasts. The medical
records of the donors from the eye bank of Yonsei Univer-
sity Severance Hospital did not show any genetic or sys-
temic metabolic disease. The fibroblasts grown from the
pieces of corneal rims were treated as healthy controls.
The corneal fibroblast cells were cultured in DMEM sup-
plemented with 10 % fetal bovine serum at 37 °C in a hu-
midified incubator with 95 % air and 5 % CO2.
Microarray and gene-expression profiling
Transcriptional profiles were evaluated in two independ-
ent cell preparations using a cDNA microarray (GeneChip
Human Gene 1.0 ST Array, GeneChip; Affymetrix, Santa
Clara, CA) containing approximately 29,000 genes. To de-
termine the variation and average changes (x-fold) in the
expression of different genes in each sample and to com-
pare the samples, we analyzed four samples (normal sam-
ple pairs 1 and 2 (age matched) and GCD2-homozygous
(Arg124His mutation) sample pairs 1 and 2) in an add-
itional microarray analysis without total RNA pooling.
Total RNA was extracted from the cells (TRIzol; Invitro-
gen, Carlsbad, CA), followed by purification (RNeasy kit;
Qiagen, Valencia, CA) to remove residual DNA. The con-
centration of total RNA was determined by UV spectropho-
tometry (ND-1000 UV–vis Spectrophotometer; Nanodrop
Technologies, Wilmington, DE). Two quality controls were
used for each RNA sample: (1) an A260/A280 ratio between
1.7 and 2.3 and (2) an electropherogram showing two dis-
tinct ribosomal peaks corresponding to 18S and 28S
RNAs, respectively, at a ratio of 28S/18S > 0.5 with min-
imal or no degradation.
100 ng of total RNA was used for the microarray
experiment. GeneChip Human Gene 1.0 ST Arrays
(Affymetrix, Santa Clara, USA) were used. Whole micro-
array experiment was performed according to the manu-
facturers protocol. The Affymetrix GeneChip Whole
Transcript (WT) sense Target Labeling Assay is designed
to generate amplified and biotynylated sense-strand DNA
targets from the entire expressed genome. Protocol is op-
timized for the use with the GeneChip Sense Target (ST)
Arrays, where the probes are distributed throughout the
entire lenght of each transcript. At first 100 ng of total
RNA was mixed with Poly-A RNA controls (GeneChip
Eukaryotic Poly-A Control Kit, Affymetrix, Santa Clara,
USA). Subsequently cDNA sysnthesis was performed with
random hexamers tagged with a T7 promoter sequence
(GeneChip WT cDNA Synthesis and Amplification Kit,
Sub-kit 1: GeneChip WT cDNA Synthesis Kit; Affymetrix,
Santa Clara, USA). The double-stranded cDNA was then
used as a template to produce many copies of antisense
cRNA (GeneChip WT cDNA Synthesis and Amplification
Kit, Sub-kit 2: GeneChip WT cDNA Amplification Kit;
Affymetrix, Santa Clara, USA). cRNA was treated with the
cleanup procedure (GeneChip IVT cRNA, cDNA Cleanup
Kit; Affymetrix, Santa Clara, USA). Subsequently cRNA
yield was determined by spectrophotometric measurement
(NanoDrop ND-1000; Thermoscientific). 10 μg of cRNA
was then used in the second cycle of cDNA synthesis. The
random hexamers were used to prime riverse transcription
of the cRNA to produce single-stranded DNA in the sense
orientation (GeneChip WT cDNA Synthesis and Amplifi-
cation Kit, Sub-kit 1: GeneChip WT cDNA Synthesis Kit;
Affymetrix, Santa Clara, USA). During this step of the pro-
cedure, in order to reproducibly fragment ssDNA, dUTP
was incorporated. Subsequently, ssDNA was then proceed
with the cleanup procedure (GeneChip IVT cRNA, cDNA
Cleanup Kit; Affymetrix, Santa Clara, USA). DNA yield
was determined by spectrophotometric measurement
(NanoDrop ND-1000; Thermoscientific).
5 μg of single-stranded DNA was treated with a com-
bination of two enzymes: uracil DNA glycosidase (UDG)
and apurinic/apyrimidinic endonuclease 1 (APE 1), spe-
cifically recognizing the dUTP nucleotides and breaking
the DNA strand (GeneChip WT Terminal Labeling Kit;
Affymetrix, Santa Clara, USA). Subsequently, fragmen-
ted DNA was labeled by terminal deoxynucleotidyl
transferase (TdT) with the DNA Labeling Reagent, that
was covalently linked to biotin (GeneChip WT Terminal
Labeling Kit; Affymetrix, Santa Clara, USA). Then frag-
mented and labeled DNA was hybridized with the Gene-
Chip Human Gene 1.0 ST Array (Affymetrix, Santa
Clara, USA). Apart from DNA, hybridization cocktail in-
cluded: Eukaryotic Hybridization Controls (bioB, bioC,
bioD, cre), Control Oligonucleotide B2 (GeneChip Hy-
bridization Control Kit; Affymetrix, Santa Clara, USA), 2x
Hybridization Mix, DMSO, water (GeneChip Hybridiza-
tion, Wash and Stain Kit- Hybridization Module; Affyme-
trix, Santa Clara, USA). Hybridization was performed in
450C/ 60 rpm/ 17 h ±1 h at hybridization oven (GeneChip
Hybridization Oven 640; Affymetrix, Santa Clara, USA).
After the hybridization, arrays were registered in Gene-
Chip Operating Software (GCOS), and subsequently
washed and stained with the use of GeneChip Fluidics Sta-
tion 450 (Affymetrix, Santa Clara, USA) and FS450_0007
protocol (GeneChip Hybridization, Wash and Stain Kit-
Stain Module; Wash Buffer A; Wash Buffer B; Affymetrix,
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Santa Clara, USA). After the wash protocol was finished
arrays were scanned with the GeneChip Scanner 3000 7G
(Affymetrix, Santa Clara, USA) controlled by GeneChip
Operating Software. The raw signal intensities were nor-
malized (GeneChip Operating Software [GCOS] algo-
rithm; Affymetrix); and the data were analyzed (Gene
Chip DNA Analysis Software [GDAS], ver. 2.0) according
to the Affymetrix GeneChip Expression Analysis Tech-
nical Manual (http://www.affymetrix.com). We detected a
twofold change in differential gene expression between
the normal and GCD2-homozygous (Arg124His mutation)
samples. Expression of ECM-associated genes (TGFBIp,
COL1A2, CTGF, and PAI-1) and H3K4 methyltransferase
genes (MLL1, MLL2, ASH1L, SMYD3, SET7/9 and SET-
MAR) is presented as the log2 ratio. For statistical ana-
lysis, we used a two-tailed, unpaired Student’s t-test
(significance threshold P < 0.05) to assess differences be-
tween the two cell types.
ShRNA infection
Lentiviruses containing human SET7/9, MLL1, and con-
trol shRNA, respectively, were purchased from Santa
Cruz Biotechnology Inc. and used to infect corneal fi-
broblasts according to the manufacturer’s instructions.
Infected cells were selected using puromycin.
Real-time quantitative reverse transcription PCR
Total RNA was isolated from corneal fibroblasts by ex-
traction in TRIZOL reagent (Invitrogen, Carlsbad, CA).
Using the Power SYBR Green RNA-to-CT™ 1-Step kit
(Applied Biosystems, Foster City, CA, USA) and StepOne-
Plus™ (Applied Biosystems, Foster City, CA, USA), mRNA
expression of GAPDH, TGFBIp, collagen type I alpha 2
(COL1A2), plasminogen activator inhibitor-1 (PAI-1), and
CTGF was measured according to the manufacturer’s in-
structions. The PCR conditions for all the genes were as
follows: 48 °C for 30 min, 95 °C for 10 min, then 40 cycles
of 95 °C for 15 s and 60 °C for 1 min. The results were
based on cycle threshold (Ct) values. We calculated the
differences between the Ct values for the experimental
genes and GAPDH (a reference gene) and graphed the re-
sults as the ratio of each RNA level to the calibrator sam-
ple level. The primers used for gene amplification were
the following: TGFBI, 5′-CACAGTCTTTGCTCCCAC
AA-3′ (sense) and 5′-CTCCGCTAACCAGGATTTCA-3′
(antisense); GAPDH, 5′-ATGGGGAAGGTGAAGGTCG-
3′ (sense) and 5′-GGGGTCATTGATGGCAACAATA-3′
(antisense); COL1A2, 5′- ATGGCTACCCAACTTGCCTT-
3′(sense) and 5′-ACAGCCTTTTTCAGGTTGCC-3′ (anti-
sense); PAI-1, 5′-CTGTCATAGTCTCAGCCCGC-3′ (sense)
and 5′-AAAGGACTGTTCCTGTGGGG-3′ (antisense);
and CTGF, 5′-GTGCATCCGTACTCCCAAAA-3′ (sense)
and 5′-ATCGGCCGTCGGTACATACT-3′(antisense). Three
independent experiments were performed, and statistical
analysis was carried out using Newman-Keuls multiple
comparison tests.
Chromatin immunoprecipitation for microarray analysis
Chromatin immunoprecipitation (ChIP) assays were per-
formed using the EpiQuik TM Chromatin Immunoprecip-
itation Kit (Epigentek) based on the protocol provided by
the supplier (Epigentek Group Inc., Brooklyn, NY). Briefly,
samples containing 4 × 106 human corneal fibroblasts
were chemically cross-linked by the addition of fresh 11 %
formaldehyde solution (1:10 volumetric ratio of solution
to sample) for 15 min at room temperature. The cells
were then rinsed twice with 1× PBS, resuspended in CP3
lysis buffer containing a protease-inhibitor cocktail, and
sonicated until the cross-linked chromatin was sheared to
an average DNA fragment length of 200–1000 bp. One
per cent of the sonicated lysate was used to quantify the
total amount of DNA present in the different samples be-
fore immunoprecipitation (input). The sonicated samples
were immunoprecipitated with H3K4me3 (Millipore,
Millipore Corp., Bedford, MA) and H3K27me3 (Abcam,
Cambridge, MA) antibodies using the EpiQuik TM Chro-
matin Immunoprecipitation Kit (Epigentek). Cross-linking
between DNA and proteins was reversed by heating the
samples at 65 °C for 15 min followed by Proteinase K di-
gestion at 65 °C for 1.5 h. After cleaning on spin columns,
the DNA was eluted in 10 mM Tris–EDTA buffer.
Chromatin immunoprecipitation microarray analysis
The immunoprecipitated and input DNA was amplified
using a whole-genome amplification kit (GenomePlex®
Complete Whole Genome Amplification Kit, Sigma,
USA) according to the manufacturer’s instructions. The
amplified samples were purified using the QIAQuick
PCR clean-up kit (Qiagen). Labeling reactions were per-
formed with 4 μg purified amplified DNA and a Bioprime
labeling kit (Invitrogen) according to the manufacturer’s
instructions in a volume of 50 μl with a modified dNTP
pool containing 120 μM each of dATP, dGTP, and dCTP;
60 μM dTTP; and 60 μM Cy5-dUTP (for the immunopre-
cipitated sample) or Cy3-dUTP (for the input sample). La-
beled targets were subsequently purified using the
QIAQuick PCR clean-up kit (Qiagen). Then, the dye-
labeled DNA samples were purified and quantified using
an ND-1000 spectrophotometer (NanoDrop Technolo-
gies, Inc., Wilmington, DE). After checking the labeling
efficiency, each sample containing 2.5–5.0 μg cyanine 3-
labeled and cyanine 5-labeled DNA target was mixed and
then resuspended with 2X hybridization buffer, Cot-1
DNA, Agilent 10X blocking agent, and de-ionized form-
amide. Before hybridization to the array, the 260-μl
hybridization mixtures were denatured at 95 °C for 3 min
and incubated at 37 °C for 30 min. The hybridization mix-
tures were centrifuged at 17,900 g for 1 min and directly
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pipetted onto the Human Promoter 1 M microarray (Agi-
lent Technology, USA). The arrays were hybridized at
65 °C for 40 h using an Agilent Hybridization oven
(Agilent Technology, USA). The hybridized microar-
rays were washed according to the manufacturer’s
protocol (Agilent Technology, USA).
Data acquisition and analysis
The hybridization images were analyzed using an Agilent
DNA Microarray Scanner (Agilent Technology, USA),
and the data were quantified using the Agilent Feature
Extraction software (Agilent Technology, USA). The pre-
processing of the raw data and the normalization steps
were performed using the Agilent Genomic Workbench
software according to the manufacturer’s instructions
(Agilent, USA). The background-corrected intensity data
were normalized by blank subtraction followed by intra-
array LOWESS normalization. The peak detection was
performed with Pre-defined Peak Shape detection v2.0
with P-value < 0.01 as the threshold of significance for a
non-parametric test and a peak-score > 5 for an EVD-
based score (based on T. Kaplan & N. Friedman
“Model-Based Analysis of High resolution Chromatin Im-
munoprecipitation” Technical Report 2006–11, School of
Computer Science & Engineering, Hebrew University 2006).
Methylated DNA isolation assay-assisted CpG microarrays
Methylated DNA isolation assay (MeDIA)-assisted CpG
microarray analysis was performed as described previ-
ously with slight modification [31]. Briefly, 1.0 μg sonic-
fragmented genomic DNA from the test and control tis-
sues, respectively, was incubated with 2 μg recombinant
MBD2bt protein for 4 h at 4 °C on a rocking platform.
The enriched, methylated DNA was amplified using a
whole-genome amplification kit (GenomePlex®, Sigma,
USA) according to the manufacturer’s protocol. The
amplified DNA in the control and test samples was la-
beled with Cy5 and Cy3, respectively. The labeled sam-
ples were purified using a PCR purification kit (Qiagen,
USA) and then co-hybridized to human promoter 1 M
microarrays (Agilent, Santa Clara, CA, USA) according
to manufacturer’s instructions.
Microarray data analysis
The hybridized images were analyzed using an Agilent
DNA Microarray Scanner (Agilent Technology, USA),
and the data were quantified using the Agilent Feature
Extraction software (Agilent Technology, USA). The
preprocessing of raw data and the normalization steps
were performed using GeneSpring 7.3.1 (Agilent, USA).
The background-corrected intensity data were normal-
ized using the intensity-dependent LOWESS method to
remove the dye bias within each array as recommended
by the manufacturer (Agilent, USA). To select the
multiple-probes-enriched target genes, the first level of
data filtering involved the removal of all probes that showed
only methylation (≥ twofold enrichment of the methylated
fraction in test samples versus control samples) or non-
methylation (≤ twofold enrichment of the non-methylated
fraction in test samples versus control samples). To in-
crease the reliability of the results, we selected genes
with probes in at least two adjacent probes.
Chromatin immunoprecipitation assays
ChIP assays were performed, and ChIP-enriched DNA
was analyzed by qPCR as described previously [32].
Briefly, cells were fixed with 1 % formaldehyde at 37 °C
for 10 min, washed with cold PBS containing protease
inhibitors, and lysed in Tris (pH 8.1) containing 1 %
SDS, 1 mM PMSF, and complete protease-inhibitor
cocktail. The cell lysates were sonicated into 500-bp
chromatin fragments, diluted in ChIP dilution buffer,
and immunoprecipitated overnight at 4 °C with the ap-
propriate antibodies, with IgG control, or without anti-
body (no-antibody control). The next day, immune
complexes were collected on ChIP-Grade Protein A/G
Magnetic Beads (Thermo Fisher Scientific Inc., Rockford,
IL USA), and the beads were washed to remove nonspe-
cific binding. The DNA was eluted from the beads, the
crosslinks were reversed, and the DNA was extracted. The
ChIP-enriched DNA samples and the input DNA samples
were analyzed by qPCR with SYBR reagent in a real-time
PCR machine (ABI 7300; Applied Biosystems) using
primers specific for the TGFBI, Col1a1, CTGF, or PAI-1
promoters spanning Smad binding elements (SBEs). All
reactions were performed in triplicate in a final volume of
20 μl. Dissociation curves were run to detect nonspecific
amplification, and we confirmed that single products were
amplified in each reaction. The qPCR data were analyzed
using the 2-ΔΔCt method, as described previously [32], and
normalized with the input samples. The results were
expressed as the fold change relative to the control. In all
of the experiments, we verified that the ChIP samples ob-
tained with specific antibodies exhibited significant en-
richment relative to the IgG or no-antibody controls. The
primers used for the ChIP-enriched DNA were: TGFBIp,
5′-TACCTGCCTTGAGCTCCTCC-3′ (sense) and 5′-GT
GGGGTCCTCACCTTGGTA-3′ (antisense); COL1A2, 5′-
CTCCGACGTGTCCCATAGTG-3′ (sense) and 5′-CTTT
TGAGGCTTTCAAGGGG-3′ (antisense); PAI-1, 5′-AGT
CTGGACACGTGGGGAGT-3′ (sense) and 5′-GCCAGC
CACGTGATTGTCTA-3′ (antisense); and CTGF, 5′-TC
TGTGAGCTGGAGTGTGCC-3′ (sense) and 5′-ACAGG
GACATTCCTCGCATT-3′ (antisense).
Western blotting
Cell lysates were fractionated by SDS-PAGE and trans-
ferred to PVDF membranes. The blocked membranes were
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incubated with the appropriate antibody, and the immuno-
reactive bands were visualized with a chemiluminescent
reagent as recommended by Amersham Biosciences, Inc.
Statistical analysis
All experiments were repeated at least three times. Data
are presented as the mean ± standard error (SE), and
statistical comparisons between groups were performed
by one-way ANOVA followed by Tukey’s test.
Results
Transcription and extracellular-secretion levels of TGFBIp
were high in wild-type cells compared with those in
GCD2 homozygous cells and were related to H3K4me3
levels but not to DNA methylation
Not only mutation of TGFBIp gene, but also regulation of
TGFBIp expression is very important cause of in GCD2.
To investigate the mechanisms of TGFBIp gene expres-
sion, we first analyzed TGFBIp mRNA transcription levels
in wild-type and GCD2-homozygous corneal fibroblasts
(Fig. 1a, b). The TGFBIp mRNA transcription levels were
much higher in the wild-type cells compared with those in
the GCD2-homozygous cells (Fig. 1c). Moreover, the
TGFBIp protein levels secreted into the culture super-
natant were much higher for the wild-type cells compared
with those for the GCD2-homozygous cells. The respect-
ive cell lysates from the wild-type and GCD2-homozygous
cells showed similar levels of TGFBIp (Fig. 1d), however,
suggesting that mutant TGFBIp accumulates in GCD2
corneal fibroblasts as a result of either impaired degrad-
ation or delayed extracellular secretion [33], causing simi-
lar intracellular TGFBIp levels in the wild-type and GCD2
homozygote cells despite the differences in TGFBIp mRNA
transcription and extracellular-secretion levels.
We next examined whether the difference in TGFBIp
gene expression was associated with changes in either
the active epigenetic marker H3K4me3 or the repressive
epigenetic marker H3K27me3 in the H3 promoter. As
Fig. 1 TGFBIp transcription and H3K4me3 levels in wild-type and GCD2-homozygous corneal fibroblasts. a, b Slit-lamp photographs and pedigree
of wild-type, GCD2 heterozygous, and GCD2 homozygous cells. c, d The mRNA and protein levels of TGFBIp in normal and GCD2 corneal fibroblasts
was determined by RT-qPCR (c) and western blot (d). Gene expression was normalized to internal control GAPDH gene, and results are expressed as
fold stimulation over control. e, f H3K4me3 and H3K27me3 levels at the Smad binding elements on TGFBIp gene promoters and at the TSS of TGFBIp
gene in wild-type and GCD2-homozygous corneal fibroblasts. ChIP assays were performed with H3K4me3 and H3K27me3 antibodies. Immunoprecipitated
DNA and input DNA were subjected to qPCR with primers specific for the TGFBIp gene promoter to measure enrichment levels. qPCR data were
analyzed using the 2-ΔΔCt method, and data are the mean fold change relative to the input ± standard error (SE) of enrichment. (mean ± SE; **P < 0.01
vs. wild type, n = 3)
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shown in Fig. 1e, f, the H3K4me3 levels in the Smad Bind-
ing Element (SBE) of the TGFBIp promoter and in the
TSS of the TGFBIp gene were much higher in the wild-
type cells compared with those in the GCD2-homozygous
cells, similar to the TGFBIp mRNA transcription levels.
The H3K27me3 levels were very low in both the wild-type
and the GCD2-homozygous cells, however, and were not
different between the two cell types. To further confirm
the association between H3K4me3 levels and TGFBIp
mRNA transcription levels, we analyzed wild-type (n = 3),
GCD2-heterozygous (n = 1), and GCD2-homozygous
(n = 3) corneal fibroblasts. As shown in Additional file 1:
Figure S1A–C, the TGFBIp mRNA transcription levels
and extracellular secreted-protein levels were much higher
in the wild-type cells compared with those in the GCD2
cells and were strongly related to the H3K4me3 levels.
The intracellular TGFBIp protein levels were not related
to the mRNA or H3K4me3 levels in the GCD2 cells, how-
ever (Additional file 1: Figure S1D).
We next performed a ChIP on chip assay with
H3K4me3-specific and H3K27me3-specific antibodies in
wild-type (n = 2) and GCD2-homozygous (n = 2) primary
corneal fibroblasts. As shown in Fig. 2a and b, the
H3K4me3 levels in the TGFBIp promoter region and
the downstream of transcription start site were high in
the wild-type cells compared with those in the GCD2
cells, but the H3K27me3 levels were very low in both the
wild-type and the GCD2 cells and were not different be-
tween the two cell types. In contrast, DNA methylation
levels in the TGFBIp promoter region were very low and
were not different between the two cell types (Fig. 2c).
Collectively, these results suggest that the mRNA tran-
scription and extracellular-secretion levels of TGFBIp
were high in the wild-type cells compared with those in
the GCD2-homozygous cells and were related to the
H3K4me3 levels but not to DNA methylation over the
TGFBI locus.
TGFβ1 increased the expression of TGFBIp and
ECM-associated genes and Smad3 recruitment to the
TGFBIp and ECM-associated gene promoters
We examined whether TGFBIp expression could be in-
duced by TGFβ1 treatment in corneal fibroblasts. As
shown in Fig. 3a and b, TGFBIp protein and mRNA
Fig. 2 H3K4me3 and H3K27me3 levels in wild-type cells compared with those in GCD2-homozygous primary corneal fibroblasts. a Heat map of
ChIP-chip signal for two wild-type and two GCD2-homozygous primary corneal fibroblasts. b Heat map of the H3K4me3-enriched TGFBIp gene
location in wild-type and GCD2 primary corneal fibroblasts. Each line represents the average H3K4me3 levels in each cell type. A continuous
X-axis indicates the location from the promoter region to downstream of the TGFBI gene. c Heat map of methylated DNA and CpG island regions
of the TGFBIp gene in primary corneal fibroblasts
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levels were significantly increased by TGFβ1 in the wild-
type cells, and the GCD2-homozygous cells showed
much lower TGFBIp levels compared with the wild-type
cells. Furthermore, As shown in Fig. 3c, the ECM-
associated genes for COL1A2, CTGF, and PAI-1 were
highly expressed together with TGFBIp in both the wild-
type and the GCD2 corneal fibroblasts. The promoters
of those ECM-associated genes contain the SBE, which
is a TGFβ1 downstream effector-signaling molecule
(Fig. 3d). Therefore, we examined whether the ECM-
associated gene expression could be induced by TGFβ1
treatment in corneal fibroblasts. As shown in Fig. 3e, the
COL1A2, PAI-1, and CTGF mRNA levels were signifi-
cantly increased by TGFβ1 in wild-type corneal fibro-
blasts, whereas the GCD2 homozygous cells showed
much smaller increases in ECM-associated gene expres-
sion levels under same conditions (Fig. 3e).
Next, we examined whether TGFβ1 altered the Smad3
occupancy on the promoters of the TGFBIp, COL1A2,
PAI-1, and CTGF genes using ChIP assays with Smad3
antibodies. As shown in Fig. 4, Smad3 recruitment was
significantly increased on the TGFBIp, COL1A2, PAI-1,
and CTGF promoters after TGFβ1 stimulation in the
GCD2-homozygous cells relative to that in the wild-type
cells (Fig. 4). The GCD2-homozygous cells showed very
small increases in Smad3 recruitment to the TGFBIp
and ECM-associated gene promoters, however (Fig. 4),
suggesting that TGFβ1 increases the expression of
TGFBIp and ECM-associated genes by increasing Smad3
recruitment to the TGFBIp and ECM-associated gene
promoters in corneal fibroblasts.
TGFβ1 enhanced H3K4me1/3 levels on the promoters of
TGFBIp and ECM-associated genes
To investigate whether TGFβ1 could alter promoter levels
of H3K4me, we performed ChIP assays with H3K4me1 or
H3K4me3 antibodies. As shown in Fig. 5a and b, TGFβ1
strongly increased H3K4me1 and H3K4me3 levels on the
TGFBIp and ECM-associated gene promoters in the wild-
type corneal fibroblasts. But only weakly increased
those levels in the GCD2-homozygous cells under the
same conditions (Fig. 5a, b). The increases in pro-
moter H3K4me1/3 levels were correlated with the in-
creased expression of the associated genes induced by
TGFβ1. In contrast, levels of the repressive epigenetic
marker H3K27me3 decreased in TGFβ1-stimulated wild-
Fig. 3 TGFβ1-induced expression of TGFBIp and ECM-associated genes in wild-type and GCD2-homozygous corneal fibroblasts. a, b Serum-depleted
wild-type and GCD2 corneal fibroblasts were stimulated with TGFβ1 (5 ng/ml) for 8 h, and protein and mRNA levels of TGFBIp were analyzed by
western blot (a) and RT-qPCR (b). b Gene expression was normalized to that of GAPDH (internal control). Results are expressed as fold stimulation
relative to the wild-type control (mean ± standard error (SE); **P < 0.01 vs. wild type, n = 3). c Total mRNA was isolated from wild-type and GCD2-
homozygous corneal fibroblasts, and gene-expression profiles were assessed using an Affymetrix gene chip. Expression of TGFBIp and ECM-associated
genes (COL1A2, CTGF, and PAI-1) is presented as the log2 ratio. d Map shows the locations of Smad binding elements (SBEs) and the primers used for
ChIP-qPCR of the TGFBIp, COL1A21, CTGF, and PAI-1 gene promoters. Open and filled boxes are Smad binding elements. Filled boxes are real engaged
positions of Smad in corneal fibroblast. e Serum-depleted wild-type and GCD2-homozygous corneal fibroblasts were stimulated with TGFβ1 (5 ng/ml)
for 8 h, and mRNA levels of ECM-associated genes (COL1A2, CTGF, and PAI-1) were analyzed by RT-qPCR. Gene expression was normalized to that of
GAPDH (internal control), and results are expressed as fold stimulation over the wild-type control (mean ± standard error (SE); **P < 0.01 vs. wild
type, n = 3)
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Fig. 4 TGFβ1 enhanced Smad3 recruitment to the TGFBIp and ECM-associated gene promoters. Smad3 recruitment at the indicated gene
promoters in wild-type and GCD2 homozygous corneal fibroblasts was stimulated by TGFβ1 (5 ng/ml) for 8 h. Smad3 recruitment was determined by
ChIP assays with Smad3 antibody. Results were normalized to the input, and Smad3 occupancy was expressed as the fold enrichment over respective
wild-type control samples (mean ± standard error (SE); **P < 0.01 vs. wild type, n = 3)
Fig. 5 TGFβ1 increased H3K4me1/3 levels on TGFBIp and ECM-associated gene promoters in wild-type and GCD2-homozygous cells. a, b Bar
graphs showing H3K4me3 (a) and H3K4me1 (b) levels at the indicated gene promoters in control and TGFβ1 (5 ng/ml)-stimulated wild-type and
GCD2-homozygous corneal fibroblasts. ChIP assays were performed with H3K4me3 and H3K4me1 antibodies. Immunoprecipitated DNA and input
DNA were subjected to qPCR with primers specific for the indicated gene promoters to measure enrichment levels. qPCR data were analyzed
using the 2-ΔΔCt method, and data are shown as the mean fold change of the input ± standard error (SE) of enrichment. (mean ± SE; **P < 0.01 vs.
wild type, n = 3)
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type corneal fibroblasts (Additional file 1: Figure S2A), but
there was no significant effect of TGFβ1 on H3K27me3
levels in the GCD2-homozygous cells (Additional file 1:
Figure S2A). Furthermore, levels of H3K9me3, another re-
pressive epigenetic marker, were not significantly changed
in either the wild-type or the GCD2-homozygous cells
under same conditions (Additional file 1: Figure S2B), sug-
gesting that increases in H3K4me1/3 and decreases in
H3K27me3 on the target-gene promoters may be involved
in the TGFβ1-induced up-regulation of TGFBIp and
ECM-associated genes in corneal fibroblasts.
TGFβ1 increased MLL1 recruitment to the TGFBIp and
ECM-associated gene promoters
To identify genes that regulate the H3K4me1/3 induced
by TGFβ1, we analyzed the expression of H3K4-
methyltransferase genes in wild-type and and GCD2 cor-
neal fibroblasts by microarray analysis. As shown in
Fig. 6a, MLL1, an H3K4 tri-methyltransferase, and SET7/
9, an H3K4 mono- methyltransferase, were expressed in
wild-type and GCD2 cells. Next, we examined whether
TGFβ1 alters the MLL1 occupancy on the promoters of
the TGFBIp, COL1A2, PAI-1, and CTGF genes using
ChIP assays with MLL1 antibodies. As shown in Fig. 6b
and c, MLL1 recruitment was significantly increased in
the TGFBIp, COL1A2, PAI-1, and CTGF promoters after
TGFβ1 stimulation in the wild-type corneal fibroblasts
(Fig. 6b, c). The GCD2 homozygous cells showed very
weak increased recruitment of MLL1 to the TGFBIp and
ECM-associated gene promoters (Fig. 6b, c). The MLL1
recruitment pattern was quite similar to the pattern of in-
creased H3K4me3 (Fig. 5a), suggesting a key role for
MLL1 in the TGFβ1-mediated increase in H3K4me3 dur-
ing the induction of the TGFBIp and ECM genes.
MLL1 and SET7/9 knockdown attenuated the
TGFβ1-induced expression of the TGFBIp and
ECM-associated genes
Corneal fibroblasts were first infected with lentivirus
containing shRNA targeting MLL1 (shMLL1) or control
shRNA (shCont), and protein levels were analyzed by
western blot. As shown in Fig. 7a, MLL1 protein levels
were significantly reduced in the wild-type and GCD2
cells infected with shMLL1 lentivirus compared with
those in wild-type and GCD2 cells infected with shCont
lentivirus. We next examined whether MLL1 shRNA
can affect H3K4me3 in corneal fibroblasts, because pre-
vious studies showed that MLL1 regulates H3K4me3 in
embryonic fibroblasts and immune cells [34–36]. Global
H3K4me3 levels were significantly reduced in both the
Fig. 6 TGFβ1 enhanced MLL1 recruitment on TGFBIp and ECM-associated gene promoters. a Total mRNA was isolated from wild-type and GCD2-
homozygous corneal fibroblasts, and gene-expression profiles were assessed using an Affymetrix gene chip. The expression levels of H3K4
methyltransferase genes are presented as the log2 ratio. b, c MLL1 recruitment to the indicated gene promoters in wild-type and GCD2 corneal
fibroblasts stimulated by TGFβ1 (5 ng/ml) for 8 h. MLL1 recruitment was determined by ChIP assays with MLL1 antibody. Results were normalized
to the input, and MLL1 occupancy was expressed as the fold enrichment over the respective wild-type control samples (mean ± standard error
(SE); **P < 0.01 vs. wild type, n = 3)
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wild-type cells and the GCD2 cells infected with
shMLL1 lentivirus (Fig. 7a). Also, TGFBIp protein levels
were reduced in cells infected with shMLL1 lentivirus.
Furthermore, shMLL1 significantly attenuated TGFβ1-
induced TGFBIp protein and mRNA levels in wild-type
corneal fibroblasts compared with shCont (Fig. 7b, c). The
GCD2-homozygous cells showed very weak TGFBIp ex-
pression and inhibition induced by TGFβ1 and shMLL1,
respectively (Fig. 7b, c). TGFβ1-induced COL1A2, PAI-1,
and CTGF mRNA levels were inhibited by shMLL1
(Fig. 7d), whereas no significant increase and decrease in
response to TGFβ1 and shMLL1 were observed in the
GCD2-homozygous cells (Fig. 7d), suggesting a key role
for MLL1 in modulating TGFβ1 responses in corneal
fibroblasts.
To investigate the role of SET7/9 in the expression of
the TGFBIp and ECM genes, cells were infected with
shSET7/9 or shCont lentivirus, and protein levels were
analyzed by western blot. As shown in Additional file 1:
Figure S3A, total H3K4me1 levels were clearly decreased
in the SET7/9 knockdown cells compared with the shCont
cells. In addition, the TGFBIp protein levels were inhibited
in the cells infected with shSET7/9 (Additional file 1:
Figure S3A). Furthermore, TGFβ1-induced TGFBIp pro-
tein and mRNA levels were inhibited by shSET7/9
(Additional file 1: Figure S3B, C) in wild-type corneal fi-
broblasts. The GCD2-homozygote cells showed very weak
TGFBIp expression and inhibition induced by TGFβ1 and
shSET7/9, respectively (Additional file 1: Figure S3B, C).
TGFβ1-induced COL1A2, PAI-1, and CTGF mRNA levels
were also partially inhibited by shSET7/9 lentivirus infec-
tion (Additional file 1: Figure S3D), whereas no significant
increase and decrease induced by TGFβ1 and shSET7/9,
respectively, was observed in the GCD2-homozygous cells
(Additional file 1: Figure S3D). Thus, SET7/9 likely par-
tially mediates the induction of H3K4me1 by TGFβ1 in
corneal fibroblasts. Collectively, these results suggest that
MLL1 and SET7/9 are involved in basal TGFBIp expres-
sion and TGFβ1-induced TGFBIp and ECM-associated
gene expression.
Fig. 7 MLL1 knockdown attenuated the TGFβ1-induced expression of TGFBIp and ECM-associated genes. a Wild-type and GCD2-homozygous
corneal fibroblasts were infected with MLL1 or control shRNA lentivirus. After puromycin selection, MLL1, H3K4me3, TGFBIp, and actin protein
levels were analyzed by western blot. b-d Wild-type and GCD2-homozygous corneal fibroblasts were infected with MLL1 or control shRNA
lentivirus. After puromycin selection, infected cells were stimulated with TGFβ1 (5 ng/ml) for 8 h, and mRNA and protein levels of TGFBIp were
analyzed by RT-qPCR (b) and western blot (c). mRNA levels of ECM-associated genes were analyzed by RT-qPCR (d). Gene expression was
normalized to that of GAPDH (internal control), and results are expressed as fold stimulation over control shRNA-infected wild-type control
(mean ± standard error (SE); **P < 0.01 vs. control, n = 3)
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MLL1 and SET7/9 knockdown attenuated the
TGFβ1-induced increase in H3K4me1/3 levels on the
promoters of the TGFBIp and ECM-associated genes
We tested whether the knockdown of MLL1 and SET7/9
can decrease active H3K4me1/3 markers on the pro-
moters of the TGFBIp and ECM-associated genes. The
knockdown of MLL1 and SET7/9 significantly decreased
TGFβ1-mediated H3K4me3 (Fig. 8a) and H3K4me1
(Additional file 1: Figure S4) levels on the TGFBIp,
COL1A2, PAI-1, and CTGF promoters. These findings
show the mediatory roles of MLL1 and SET7/9 in TGFβ1-
induced epigenetic events on the promoters of the
TGFBIp and ECM genes and in the subsequent expression
of those genes.
To better understand the roles of MLL1 and SET7/9
in TGFBIp expression, cells were co-infected with shMLL1
and shSET7/9, and TGFBIp mRNA levels were analyzed
by RT-qPCR. As shown in Fig. 8b, shMLL1 and shSET7/9
co-infection completely inhibited TGFβ1-induced TGFBIp
mRNA levels compared with shMLL1 or shSET7/9 single
infection, providing evidence that both MLL1 and SET7/9
mediate TGFβ1-induced TGFBIp expression by regulating
H3K4me1/3.
Discussion
In GCD2 pathogenesis, mutations in the TGFBI gene
important, but the regulation of TGFBIp expression is
also very important. We confirmed that mRNA tran-
scription and extracellular-secretion levels of TGFBIp
were high in wild-type corneal fibroblasts compared
with those in GCD2-homozygous cells. The expression
pattern was strongly related to H3K4me3 levels but not
Fig. 8 MLL1 knockdown attenuated TGFβ1-induced increases in H3K4me3 on the promoters of TGFBIp and ECM-associated genes. a Wild-type
and GCD2-homozygous corneal fibroblasts were infected with MLL1 or control shRNA lentivirus. After puromycin selection, infected cells were
stimulated with TGF-β1 (5 ng/ml) for 8 h, and H3K4me3 levels at the indicated gene promoters were analyzed. ChIP assays were performed with
H3K4me3 antibody. Immunoprecipitated DNA and input DNA were subjected to qPCR with primers specific for the indicated gene promoters to
measure enrichment levels. qPCR data were analyzed using the 2-ΔΔCt method, and data are presented as mean fold change of the input ± standard
error (SE) of enrichment. (mean ± SE; **P < 0.01 vs. control, n = 3). b Wild-type and GCD2-homozygous corneal fibroblasts were double infected with
MLL1 and SET7/9 or control shRNA lentivirus. After puromycin selection, infected cells were stimulated with TGFβ1 (5 ng/ml) for 8 h, and mRNA levels
of TGFBIp were analyzed by RT-qPCR. Gene expression was normalized to that of GAPDH (internal control), and results are expressed as fold stimulation
over control shRNA-infected wild-type control (mean ± standard error (SE); **P < 0.01 vs. control, n = 3) (c) A model showing that in corneal fibroblasts
reaching the quiescent state, transcriptional repression of TGFBIp and ECM-associated genes occurs through heterochromatin formation under no
stimulation. Lysine 27 from histone H3 (H3K27) near Smad binding elements (SBEs) within promoters was tri-methylated. During TGFβ1 stimulation,
MLL1 and SET7/9 were activated, and their recruitment to SBEs was increased and recruitment of Smad to SBEs was increased. H3K4me1/3 became
more methylated, and H3K27me3 was de-methylated on the gene promoters, creating a favorable environment for Smad3 binding
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to DNA methylation over the TGFBI locus. Intracellular
TGFBIp levels were similar in wild-type and GCD2-
homozygous cells, although TGFBIp mRNA transcrip-
tion and extracellular secreted-protein levels were much
lower in GCD2-homozygous cells compared with wild-
type cells, because mutant TGFBIp can accumulate in
GCD2 corneal fibroblasts as a result of either impaired
degradation or delayed extracellular secretion [33]. The
abnormal conditions within GCD2 cells caused by
mutant-TGFBIp accumulation may weaken responses to
exogenous stimuli such as TGFβ1 compared with those
in wild-type cells.
Alternately, the observed differences in histone modifi-
cation in GCD2 fibroblasts compared to normal cells
may be due to the reduced expression of TGFBI in the
mutant cells. Much less TGFBIp is secreted from mutant
than from wild type cells. However, intracellular TGFBIp
is at similar levels in both cell types. Given the reduced
secretion of the protein in mutant cells, less transcrip-
tion is required to maintain intracellular protein levels
and negative feedback would suppress transcription in
mutant relative to wild type cells. Thus, it is expected
that levels of H3K4me3, a well-known marker of active
transcription, would be reduced at the promoter of the
TGFBI gene. Our data show that the transcription of
TGFBI and associated ECM genes is increased upon
treatment with TGFβ1 and that H3K4me3 levels again
correlate with expression. These effects are reduced, but
not eliminated, in mutant cells. The association of active
histone modifications with levels of transcription may
not represent proof of a causative link. Rather, it is more
likely that the accumulation of TGFBIp is driving the al-
tered transcription pattern in mutant cells.
In our study, we found that TGFβ1 can up-regulate
TGFBIp and ECM-associated genes such as COL1A2,
PAI-1, and CTGF in corneal fibroblasts. TGFBIp expres-
sion induced by TGFβ1 was seen previously in corneal
fibroblasts, but our study is the first to demonstrate in-
creases in the expression of other ECM genes that may
coagulate with TGFBIp in the corneas of patients with
GCD2. We observed that TGFβ1 increased Smad3 re-
cruitment to the TGFBIp and ECM-associated gene
promoters in corneal fibroblasts. TGFBIp and ECM-
associated genes have conserved SBEs in their promoters,
suggesting that gene expression could be similarly regu-
lated under conditions such as TGFβ1 stimulation.
We examined changes in key epigenetic chromatin
markers, including H3K27me3 and H3K4me1/3 levels, on
the TGFBIp and ECM-associated gene promoters. Our re-
sults showed that those markers, along with H3K27 his-
tone de-methylases (HDMs) and the MLL1 and SET7/9
HMTs, are involved in the TGFβ1-induced up-regulation
of TGFBIp and ECM-associated genes in corneal fibro-
blasts. We showed that the up-regulation of H3K4me1/3
markers usually associated with active chromatin occurs
in parallel with the down-regulation of H3K27me3 by
TGFβ1, suggesting that those regulatory mechanisms can
further contribute to the increased gene expression. Re-
cent studies showed that methylated H3K4 correlates with
transcriptionally competent chromatin and is associated
with active genes [25–27], supporting our observation that
TGFβ1 increased the expression of the TGFBIp and ECM
genes in corneal fibroblasts and that such expression
was positively correlated with increased H3K4me1and
H3K4me3 levels on the associated promoters.
Increasing evidence shows that H3K27me3 markers
are recognized by polycomb protein and generally cor-
relate with gene silencing and transcriptional repression
[26, 37, 38]. Our results showed for the first time that
TGFβ1 decreased H3K27me3 levels on the TGFBIp and
ECM gene promoters and that those levels were in-
versely correlated with the increased expression of the
genes, further supporting the notion that a relief of tran-
scriptional repression caused by decreases in repressive
chromatin histone modifications may contribute to the
increased expression of TGFBIp and ECM genes induced
by TGFβ1. Collectively, our observations show that in-
creases in H3K4me1/3 and decreases in H3K27me3 at the
TGFBIp and ECM gene promoters in the presence of
TGFβ1 in corneal fibroblasts are correlated with the
TGFβ1-induced up-regulation of those genes.
Furthermore, we showed not only an increase in the
recruitment of the H4K4 HMTs MLL1 and SET7/9 at
the TGFBIp and ECM gene promoters but also a de-
crease in the recruitment of H4K27 HMT in corneal fi-
broblasts stimulated by TGFβ1, suggesting that the
H4K4 HMT MLL1 is involved in the TGFβ1-induced
up-regulation of the TGFBIp and ECM genes in corneal
fibroblasts. This was supported by our observations that
MLL1 and SET7/9 gene silencing partially, but signifi-
cantly, blocked the expression of the TGFβ1-induced
TGFBIp and ECM genes. The knockdown of MLL1 and
SET7/9 with shRNAs could decrease global H3K4me1
and H3K4me3 levels, suggesting that H3K4me1/3 medi-
ated by MLL1 and SET7/9 plays a key role in TGFBIp
and ECM-associated gene expression and that MLL1
and SET7/9 are potential therapeutic targets for the
treatment of ECM-accumulation disorders such as GCD2.
The observed increases in H3K4me3 might synergize with
other complementary events occurring on the TGFBIp
and ECM-associated gene promoters, such as increases in
H3K4me1 and decreases in H3K27me3, to enhance
TGFBIp and ECM gene expression in response to TGFβ1.
In addition, the HMTs and HDMs, as well as the HATs
and histone deacetylases, regulating the complementary
chromatin markers may also play cooperative roles. Add-
itional studies are needed to assess those factors, including
the role of the HMTs that mediate H3K4me1/3 and
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H3K27me3. It was suggested that the H3K4me1/3 medi-
ated by MLL1 and SET7/9 functions in transcriptional ac-
tivation by competing with histone deacetylases to
enhance H3-K9 acetylation and prevent H3-K9 methyla-
tion [39, 40]. MLL1 and SET7/9 can methylate non-
histone proteins including p53 [41, 42], DNMT1 [43],
TAF10 [44], and p65 [45, 46]. Furthermore, MLL1 and
SET7/9 could regulate a subset of TNFα-induced, NF-κB-
dependent inflammatory genes in monocytes [47] and the
high glucose-induced expression of NF-κB p65 and in-
flammatory genes in endothelial cells [48], indicating the
diverse physiologic roles of MLL1 and SET7/9 in gene
transactivation. Similarly, MLL1 and SET7/9 may also
methylate other non-histone proteins and possibly even
Smads in corneal fibroblasts. Further studies are needed
to evaluate those possibilities. In the future, analogous ap-
proaches should be explored to examine epigenetic mech-
anisms of regulating the expression of other matrix genes
in corneal epithelial cells exposed to TGFβ1. Epigenetic
mechanisms may affect ECM expression by regulating the
expression of metalloproteases and other proteases, be-
cause histone modification has been shown to regulate
metalloproteases in some cells [49]. Taken together, our
results show that TGFβ1 can promote significant changes
in H3K4 and H3K27 methylation on gene promoters in
corneal fibroblasts that correlate with parallel increases in
the expression of genes related to ECM accumulation and
GCD2 pathogenesis.
Conclusions
In summary, our findings clearly show that epigenetic his-
tone methylation modulates the expression of TGFBIp
and ECM genes in corneal fibroblasts. In corneal fibro-
blasts reaching the quiescent state, the transcriptional re-
pression of TGFBIp and ECM-associated genes occurs
through heterochromatin formation with no external
stimulation. H3K27 residues near SBEs within promoters
are tri-methylated. During TGFβ1 stimulation, MLL1 and
SET7/9 are activated, increasing their recruitment to
SBEs. H3K4me1/3 becomes more methylated, and
H3K27me3 becomes de-methylated on gene promoters,
creating a favorable environment for Smad3 binding,
resulting in the increased expression of TGFBIp and
ECM-associated genes (Fig. 8c). The effective epigenetic
regulation of histone H3K4me during the TGFβ1-
mediated expression of TGFBIp and ECM genes in cor-
neal fibroblasts could be used to create cornea-protective
therapies for granular corneal dystrophy.
Additional file
Additional file 1: Figure S1. TGFBIp transcription was high in wild-type
cells compared with that in GCD2 corneal fibroblasts and was related to
H3K4me3 levels. (A) H3K4me3 levels at the Smad binding elements of
TGFBIp gene promoters in wild-type, GCD2-heterozygous, and GCD2-
homozygous corneal fibroblasts. ChIP assays were performed with
H3K4me3 antibody. (mean ±SE). (B) mRNA levels of TGFBIp in corneal
fibroblasts were determined by RT-qPCR. (C, D) Protein levels of TGFBIp in
cell lysates or culture supernatants were determined by western blot.
Figure S2. TGFb1 had a minor effect on H3K27me3 and H3K9me3
modification on the TGFBIp and ECM-associated gene promoters. Bar
graphs showing H3K27me3 (A) and H3K9me3 (B) levels on the indicated
gene promoters in control and TGFb1 (5 ng/ml)-stimulated corneal
fibroblasts. ChIP assays were performed with H3K27me3 and H3K9me3
antibodies. (mean ±SE; **P < 0.01 vs. control, n = 3). Figure S3. SET7/9
knockdown attenuated the TGFb1-induced expression of TGFBIp and
ECM-associated genes. Wild-type and GCD2-homozygous corneal
fibroblasts were infected with SET7/9 or control shRNA lentivirus. After
puromycin selection, SET7/9, H3K4me1, TGFBIp, and actin protein levels
were analyzed by western blot (A) and infected cells were stimulated
with TGFb1 (5 ng/ml) for 8 h, and mRNA and protein levels of TGFBIp
were analyzed by RT-qPCR (B) and western blot (C). mRNA levels of ECM
associated genes were analyzed by RT-qPCR (D). (mean ±standard error
(SE); **P < 0.01 vs. control, n = 3). Figure S4. SET7/9 knockdown
attenuated TGFb1-induced increases in H3K4me1 levels at the promoters
of TGFBIp and ECM-associated genes. SET7/9 or control shRNA lentivirus
infected cells were stimulated with TGFb1 (5 ng/ml) for 8 h, and
H3K4me1 levels at the indicated gene promoters were analyzed. ChIP
assays were performed with H3K4me1 antibody. (mean ± SE); **P < 0.01
vs. control, n = 3).
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